KR940006578A - 2-(3,4-디메톡신나모일) 아미노벤조산 - Google Patents

2-(3,4-디메톡신나모일) 아미노벤조산 Download PDF

Info

Publication number
KR940006578A
KR940006578A KR1019930018347A KR930018347A KR940006578A KR 940006578 A KR940006578 A KR 940006578A KR 1019930018347 A KR1019930018347 A KR 1019930018347A KR 930018347 A KR930018347 A KR 930018347A KR 940006578 A KR940006578 A KR 940006578A
Authority
KR
South Korea
Prior art keywords
treatment
tranilast
acceptable salt
pharmacologically acceptable
aminobenzoic acid
Prior art date
Application number
KR1019930018347A
Other languages
English (en)
Other versions
KR100252410B1 (ko
Inventor
히데오 다마이
긴조 우에다
융쉥 슈
Original Assignee
긴자와 무츠오
깃세이 야쿠힝 고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 긴자와 무츠오, 깃세이 야쿠힝 고교 가부시키가이샤 filed Critical 긴자와 무츠오
Publication of KR940006578A publication Critical patent/KR940006578A/ko
Application granted granted Critical
Publication of KR100252410B1 publication Critical patent/KR100252410B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

본 발명은 활성성분으로서 트라닐라스트 또는 이것의 약리학적으로 수용할 수 있는 염으로 이루어진 관상동맥의 조정과 관련된 재협착의 치료 또는 예방을 위한 약리학적 조성물을 제공하고 관상동맥의 조정과 관련된 재협착의 치료 또는 예방을 위한 약제의 제조를 위한 트라닐라스트 또는 이것의 약리학적으로 수용할수 있는 염의 용도를 제공한다. 관상동맥의 조정후 연속적으로 3개월의 치료기간동안 트라닐라스트의 600mg 투약량은 재협착의 발생을 줄이고 환자의 협착 정도를 감소시킨다.

Description

2-(3,4-디메톡시신나모일)아미노벤조산
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (2)

  1. 활성성분으로서 2-(3,4-디메톡시신나모일)아미노벤조산 또는 이것의 약리학적으로 수용할 수 있는 염으로 이루어진 관상동맥의 조정과 관련된 재협착의 치료 또는 예방을 위한 약리학적 조성물.
  2. 관상동맥의 조정과 관련된 재협착의 치료 또는 예방을 위한 약제의 제조를 위한 2-(3,4-디메톡시신나모일)아미노벤조산 또는 이것의 약리학적으로 수용할 수 있는 염의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930018347A 1992-09-14 1993-09-13 관상동맥수술후의 재협착의 치료 또는 예방을 위한 약학적 조성물 KR100252410B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP4288086A JP2617407B2 (ja) 1992-09-14 1992-09-14 血管内膜細胞過剰増殖疾患の予防および治療剤
JP92-288086 1992-09-14

Publications (2)

Publication Number Publication Date
KR940006578A true KR940006578A (ko) 1994-04-25
KR100252410B1 KR100252410B1 (ko) 2000-05-01

Family

ID=17725612

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930018347A KR100252410B1 (ko) 1992-09-14 1993-09-13 관상동맥수술후의 재협착의 치료 또는 예방을 위한 약학적 조성물

Country Status (7)

Country Link
US (1) US5385935A (ko)
EP (1) EP0588518B1 (ko)
JP (1) JP2617407B2 (ko)
KR (1) KR100252410B1 (ko)
CA (1) CA2106172C (ko)
DE (1) DE69310065T2 (ko)
HK (1) HK1005425A1 (ko)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6197789B1 (en) 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
ATE406909T1 (de) * 1993-05-13 2008-09-15 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US5824644A (en) * 1994-07-07 1998-10-20 G. D. Searle & Co. Method of attenuating arterial stenosis
US20030083733A1 (en) * 1997-10-10 2003-05-01 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US20020091433A1 (en) * 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US7611533B2 (en) * 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
NZ331339A (en) * 1996-02-15 2001-02-23 Kissei Pharmaceutical Neovascularization inhibitor comprising N-(3, 4-dimethoxycinnamoyl)anthranilic acid
JPH09278653A (ja) * 1996-04-05 1997-10-28 Santen Pharmaceut Co Ltd 網膜疾患治療剤
US6019104A (en) * 1996-12-30 2000-02-01 Kissei Pharmaceutical Co., Ltd. Method for the treatment or prevention of restenosis associated with coronary intervention
WO1998035668A1 (fr) * 1997-02-14 1998-08-20 Kissei Pharmaceutical Co., Ltd. Medicaments entravant l'evolution du pterygion et sa recurrence postoperatoire
US6511477B2 (en) * 1997-03-13 2003-01-28 Biocardia, Inc. Method of drug delivery to interstitial regions of the myocardium
RU2207852C2 (ru) * 1997-04-18 2003-07-10 Киссеи Фармасьютикал Ко., Лтд. Средства для предотвращения или лечения болезней, связанных с чрезмерной пролиферацией эпителиальных пигментных клеток сетчатки
JP4583597B2 (ja) * 1998-05-05 2010-11-17 ボストン サイエンティフィック リミテッド 末端が滑らかなステント
PL349926A1 (en) * 1999-02-03 2002-10-21 Smithkline Beecham Corp Method for the prevention or reduction of cardiovascular events associated with coronary intervention
JP2002536327A (ja) * 1999-02-03 2002-10-29 スミスクライン・ビーチャム・コーポレイション 冠状動脈インターベンションに伴う心臓血管事象の予防または軽減方法
EP1197210B1 (en) 1999-07-16 2005-10-05 Kissei Pharmaceutical Co., Ltd. Agents inhibiting chronic rejection reactions after organ transplantation
US6767544B2 (en) 2002-04-01 2004-07-27 Allergan, Inc. Methods for treating cardiovascular diseases with botulinum toxin
US20060216313A1 (en) * 1999-08-10 2006-09-28 Allergan, Inc. Methods for treating a stricture with a botulinum toxin
AU2001243248A1 (en) * 2000-02-23 2001-09-03 Smith Kline Beecham Corporation Method for the prevention or reduction of vascular access dysfunction
US6613083B2 (en) * 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
JP2005531391A (ja) * 2002-06-27 2005-10-20 微創医療器械（上海）有限公司 薬剤放出ステント
US20080306126A1 (en) * 2004-01-05 2008-12-11 Fonseca Vivian A Peroxisome proliferator activated receptor treatment of hyperhomocysteinemia and its complications
US7473738B2 (en) * 2004-09-30 2009-01-06 Johnson & Johnson Vision Care, Inc. Lactam polymer derivatives
US8883190B2 (en) * 2006-12-01 2014-11-11 Wake Forest University Health Sciences Urologic devices incorporating collagen inhibitors
WO2010147184A1 (ja) 2009-06-17 2010-12-23 国立大学法人熊本大学 月経困難症の予防及び／又は治療薬

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4070484A (en) * 1973-01-18 1978-01-24 Kissei Pharmaceutical Co., Ltd. Antiallergic composition containing aromatic carboxylic amide derivatives and method of using the same
JPS5640710B2 (ko) * 1973-01-18 1981-09-22
US4337270A (en) * 1980-05-21 1982-06-29 Hisamitsu Pharmaceutical Co., Inc. Novel anthranilic acid derivatives

Also Published As

Publication number Publication date
EP0588518A1 (en) 1994-03-23
EP0588518B1 (en) 1997-04-23
DE69310065D1 (de) 1997-05-28
HK1005425A1 (en) 1999-01-08
KR100252410B1 (ko) 2000-05-01
JP2617407B2 (ja) 1997-06-04
DE69310065T2 (de) 1997-11-20
CA2106172A1 (en) 1994-03-15
US5385935A (en) 1995-01-31
CA2106172C (en) 2001-01-02
JPH06135829A (ja) 1994-05-17

Similar Documents

Publication Publication Date Title
KR940006578A (ko) 2-(3,4-디메톡신나모일) 아미노벤조산
EP1649853A3 (en) Microtubule stabilizing agents for treating atherosclerosis or restenosis
KR920019342A (ko) 골질환 치료제
ZA919317B (en) Novel hydroxamic acid and N-hydroxyurea derivatives and their use.
ATE292463T1 (de) L-carnitin oder ihre derivate und resveratrol oder ihre derivate zur vorbeugung und behandlung von kardiovaskulären erkrankungen, peripheren gefässkrankheit, peripheren diabetischen neuropathie und diese enthaltende pharmazeutische zusammensetzungen
PT750618E (pt) Derivados de oxazolidinona e composicoes farmaceuticas que os contem
ES2192234T3 (es) Composiciones farmaceuticas parenterales conteniendo sales de amonioalquilo de acidos 2-arilpropionicos.
KR920017655A (ko) 상처의 치료를 촉진시키기 위한 약학 조성물
KR910019620A (ko) 15-케토-프로스타글란딘 화합물을 사용한 췌장 질병의 치료
NO924066D0 (no) Terapeutisk middel
DE69113466D1 (de) Sulfonanilidderivat und arzneimittel.
DE69627160D1 (de) Pharmazeutische zusammensetzung enthaltend 3-(2,2,2-trimethylhydrazinium)proprionat und gamma-butyrobetain für die behandlung von herz-gefäss-erkrankungen
DK0561882T3 (da) Hydroxamsyrederivater, som inhiberer lipoxygenase
KR920019365A (ko) 디리트로마이신을 함유하는 약학 제형
AR009446A1 (es) Utilizacion del acido 2-(3,4-dimetoxinamoil)aminobenzoico (tranilast) en la fabricacion de un medicamento para el tratamiento o prevencion de larestenosis, composicion farmaceutica y procedimiento de preparacion.
BR9813020A (pt) Utilização de derivados de ácido lisofosfatidìlico, compostos e drogas que contém esses compostos
KR950007852A (ko) 우라실을 유효성분으로 함유하는 관절염 치료제
KR940003550A (ko) 노인성 치매 예방 및 치료방법
HUP0000716A2 (hu) Fekélyes kolitisz és/vagy Crohn-féle betegség megelőzésére és kezelésére alkalmas gyógyszerkészítmény
KR930019216A (ko) 종양 치료제
HUP0200148A2 (hu) N-(3',4'-dimetoxi-cinnamoil)antranilsav alkalmazása szívkoszorúér-műtéttel kapcsolatos cardiovascularis események megelőzésére vagy mérséklésére
UA30143C2 (uk) Лікувальний препарат для профілактики та лікування інфекційних та запальних захворювань
ES2119086T3 (es) Uso de quinonas para la fabricacion de un medicamento para el tratamiento y prevencion de una rinitis alergica.
BR9206978A (pt) Composição farmacêutica para inibir infecção com vírus da aids
KR880012228A (ko) 천식 치료제

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee